These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
135 related items for PubMed ID: 1798236
1. Comparative biological activities of acellular pertussis vaccines produced by Kitasato. Watanabe M, Izumiya K, Sato T, Yoshino K, Nakagawa N, Ohoishi M, Hoshino M. Kitasato Arch Exp Med; 1991 Apr; 64(1):31-42. PubMed ID: 1798236 [Abstract] [Full Text] [Related]
2. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis. Trollfors B, Taranger J, Lagergård T, Sundh V, Bryla DA, Schneerson R, Robbins JB. Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077 [Abstract] [Full Text] [Related]
3. Serological responses to infection with B. pertussis. Giammanco A, Taormina S, Genovese M, Mangiaracina G, Giammanco G, Chiarini A. Dev Biol Stand; 1997 Mar; 89():213-20. PubMed ID: 9272353 [Abstract] [Full Text] [Related]
4. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis. Knight JB, Huang YY, Halperin SA, Anderson R, Morris A, Macmillan A, Jones T, Burt DS, Van Nest G, Lee SF. Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625 [Abstract] [Full Text] [Related]
5. Comparison of toxicities of acellular pertussis vaccine with whole cell pertussis vaccine in experimental animals. Sato Y, Sato H. Dev Biol Stand; 1991 Jun; 73():251-62. PubMed ID: 1778317 [Abstract] [Full Text] [Related]
6. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis. Morokuma K, Ginnaga A, Nishihara T, Tsunoda S, Furukawa M, Aihara K, Sakoh M. Dev Biol Stand; 1991 Jun; 73():223-32. PubMed ID: 1685713 [Abstract] [Full Text] [Related]
7. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine. Auerbach BS, Lake AM, Wilson ME, Willingham FF, Shematek J, Moulton L, Deforest A, Halsey NA. Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522 [Abstract] [Full Text] [Related]
9. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Meade BD, Deforest A, Edwards KM, Romani TA, Lynn F, O'Brien CH, Swartz CB, Reed GF, Deloria MA. Pediatrics; 1995 Sep; 96(3 Pt 2):570-5. PubMed ID: 7659478 [Abstract] [Full Text] [Related]
10. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042 [Abstract] [Full Text] [Related]
11. Anti-pertussis toxin IgG and anti-filamentous hemagglutinin IgG production in children immunized with pertussis acellular vaccine and comparison of these titers with the sera of pertussis convalescent children. Sato Y, Sato H. Dev Biol Stand; 1985 Dec; 61():367-72. PubMed ID: 3835079 [Abstract] [Full Text] [Related]
12. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough. Winsnes R, Lønnes T, Møgster B, Berdal BP. Dev Biol Stand; 1985 Dec; 61():353-65. PubMed ID: 2872124 [Abstract] [Full Text] [Related]
13. Japanese clinical trials with Takeda acellular pertussis vaccine. Kuno-Sakai H, Kimura M, Ozaki K, Isomura S, Kamiya H, Nii R, Kato T, Horiuchi K, Syukuda Y, Fujita I. Tokai J Exp Clin Med; 1988 Dec; 13 Suppl():15-9. PubMed ID: 2908519 [Abstract] [Full Text] [Related]
14. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin. Ginnaga A, Morokuma K, Aihara K, Sakou M, Imaizumi A, Suzuki Y, Sato H, Sato Y, Ueda K, Kuno-Sakai H. Tokai J Exp Clin Med; 1988 Dec; 13 Suppl():59-69. PubMed ID: 2908528 [Abstract] [Full Text] [Related]
15. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis. Sato H, Sato Y. Dev Biol Stand; 1985 Dec; 61():461-7. PubMed ID: 2872127 [Abstract] [Full Text] [Related]
16. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. J Infect Dis; 2004 Jul 15; 190(2):335-40. PubMed ID: 15216470 [Abstract] [Full Text] [Related]
17. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques. Gupta RK, Saxena SN, Sharma SB, Ahuja S. Dev Biol Stand; 1991 Jul 15; 73():205-22. PubMed ID: 1778314 [Abstract] [Full Text] [Related]
18. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines. Gupta RK, Anderson R, Cecchini D, Rost B, Griffin P, Benscoter K, Xu J, Montanez-Ortiz L, Siber GR. Dev Biol Stand; 1996 Jul 15; 86():283-96. PubMed ID: 8785957 [Abstract] [Full Text] [Related]
19. Optimization of immunization schedule to standardize antibody response in mice to pertussis vaccines. Tiru M, Jäätmaa E, Gillenius P, Askelöf P. Dev Biol Stand; 1985 Jul 15; 61():469-75. PubMed ID: 2872128 [Abstract] [Full Text] [Related]